VGXI
VGXI is a The Woodlands, Texas-based contract research organization company wholly owned by GeneOne Life Science.
All edits
January 29, 2020
The company announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV) that has recently emerged in Wuhan, China under an agreement executed with Inovio Pharmaceuticals . A grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) will fund the vaccine development, manufacturing, and early stage clinical testing as part of the collaborative effort led by Inovio.
VGXI
VGXI is a The Woodlands, Texas-based contract research organization company wholly owned by GeneOne Life Science.
VGXI is a wholly-owned subsidiary of GeneOne Life Science, a South Korea-based company. VGXI is a specialized contract research organization specialized in producing plasmid DNA.
Find more companies like VGXI
